ANTERIS TECHNOLOGIES GLOBAL CORP. - Announcements

6.26%

$5.60

Market Cap $86.68M

Healthcare Medical Devices

Anteris Technologies Global Corp. is a structural heart company, which is engaged in... Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

AVR	Admedus End of Year Update	PRICE SENSITIVE	24/12/13	278.97KB	Share
AVR	Admedus Acquires Manufacturing Facility	PRICE SENSITIVE	12/12/13	223.93KB	Share
AVR	Allied makes first sale of CardioCel into Europe	PRICE SENSITIVE	08/11/13	184.28KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/13	467.99KB	Share
AVR	Response to ASX price query	PRICE SENSITIVE	25/10/13	326.34KB	Share
AVR	Allied Herpes Phase I Trial progress update	PRICE SENSITIVE	17/10/13	269.31KB	Share
AVR	8 Surgeons get approval to use CardioCel in adult patients	PRICE SENSITIVE	08/10/13	199.58KB	Share
AVR	5 year extension data for Allied's CardioCel	PRICE SENSITIVE	25/09/13	288.61KB	Share
AVR	Non-Renounceable Issue Offer Document	PRICE SENSITIVE	23/09/13	501.27KB	Share
AVR	Allied announces fully underwritten Rights Issue	PRICE SENSITIVE	23/09/13	312.62KB	Share
AVR	Allied Herpes Vaccine Phase I Trial Update	PRICE SENSITIVE	03/09/13	194.72KB	Share
AVR	Annual Report to shareholders and Appendix 4E	PRICE SENSITIVE	30/08/13	1.94MB	Share
AVR	Allied granted CE Mark for CardioCel	PRICE SENSITIVE	26/08/13	201.44KB	Share
AVR	Response to ASX price query	PRICE SENSITIVE	20/08/13	332.66KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	30/07/13	469.16KB	Share
AVR	Allied increases stake in Ian Frazer's Coridon vaccines	PRICE SENSITIVE	01/07/13	196.14KB	Share
AVR	Allied's Herpes Vaccine Progresses to Phase 1 Clinical Trial	PRICE SENSITIVE	19/06/13	181.05KB	Share
AVR	Allied's CardioCel receives $1.9M grant	PRICE SENSITIVE	03/06/13	225.42KB	Share
AVR	Allied's CardioCel in Spotlight at International Conferences	PRICE SENSITIVE	06/05/13	202.44KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	29/04/13	470.69KB	Share
AVR	Allied Announces Additional Early Access for CardioCel	PRICE SENSITIVE	08/04/13	278.62KB	Share
AVR	Clinical Trial Extension Study Update - No Calcification	PRICE SENSITIVE	06/03/13	202.33KB	Share
AVR	Half Yearly Report	PRICE SENSITIVE	22/02/13	134.2KB	Share
AVR	Response to ASX query	PRICE SENSITIVE	19/02/13	352.13KB	Share
AVR	Allied announces ISO 13485 certification for CardioCel	PRICE SENSITIVE	13/02/13	202.01KB	Share
AVR	Allied's CardioCel superior for seeding stem cells	PRICE SENSITIVE	06/02/13	704.27KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/13	449.71KB	Share
AVR	Allied's hernia and pelvic floor results	PRICE SENSITIVE	10/01/13	280.04KB	Share
AVR	Allied announces successful grant for Coridon's HPV vaccine	PRICE SENSITIVE	20/12/12	266.22KB	Share
AVR	Allied Announces Placement and Share Purchase Plan	PRICE SENSITIVE	17/12/12	207.44KB	Share
AVR	Trading Halt	PRICE SENSITIVE	13/12/12	75.83KB	Share
AVR	Allied's CardioCel shows regeneration in heart valve study	PRICE SENSITIVE	28/11/12	221.5KB	Share
AVR	Allied announces successful result for Coridon's HPV vaccine	PRICE SENSITIVE	15/11/12	272.32KB	Share
AVR	New contract signals strong year of sales for Allied	PRICE SENSITIVE	07/11/12	252.63KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/12	448.04KB	Share
AVR	First patients receive Allied's CardioCel	PRICE SENSITIVE	18/10/12	185.72KB	Share
AVR	Allied's CardioCel authorised for early use in patients	PRICE SENSITIVE	26/09/12	198.92KB	Share
AVR	Preliminary Final Report	PRICE SENSITIVE	31/08/12	580.42KB	Share
AVR	Appendix 4C - Fourth Quarter Report	PRICE SENSITIVE	31/07/12	467.39KB	Share
AVR	Allied and CSIRO announce stem cell collaboration	PRICE SENSITIVE	03/07/12	257.49KB	Share
AVR	Allied submits CE Mark application for CardioCel	PRICE SENSITIVE	05/06/12	74.89KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/12	465.2KB	Share
AVR	Allied increases stake in Coridon	PRICE SENSITIVE	27/04/12	266.18KB	Share
AVR	Allied closes Rights Issue Capital Raising	PRICE SENSITIVE	24/04/12	274.56KB	Share
AVR	Allied announces Coridon license to vector technology	PRICE SENSITIVE	17/04/12	278.69KB	Share
AVR	Positive Phase II follow up data from CardioCel	PRICE SENSITIVE	05/04/12	182.33KB	Share
AVR	Allied announces successful implant of GyneCel	PRICE SENSITIVE	29/03/12	269.02KB	Share
AVR	Offer Document for Non-Renounceable Rights Issue	PRICE SENSITIVE	21/03/12	520.16KB	Share
AVR	Allied announces ADAPT Patent granted for Singapore	PRICE SENSITIVE	19/03/12	346.75KB	Share
AVR	Allied undertake capital raise includes notice under S708AA	PRICE SENSITIVE	16/03/12	275.71KB	Share
AVR	Trading Halt	PRICE SENSITIVE	14/03/12	22.23KB	Share
AVR	Allied announces successful implant of CardioCel	PRICE SENSITIVE	13/03/12	182.38KB	Share
AVR	Allied announces updated regulatory strategy for CardioCel	PRICE SENSITIVE	05/03/12	183.35KB	Share
AVR	Half Yearly Report and Accounts	PRICE SENSITIVE	01/03/12	127.73KB	Share
AVR	Allied's Coridon to develop HPV Vaccine	PRICE SENSITIVE	28/02/12	153.51KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/12	526.44KB	Share
AVR	Positive Results in Tissue Heart Valve Study	PRICE SENSITIVE	05/12/11	556.76KB	Share
AVR	Allied Healthcare Group Appoints a New CEO of Celxcel	PRICE SENSITIVE	22/11/11	332.05KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/11	526.1KB	Share
AVR	Allied Healthcare Increases Holding in Coridon	PRICE SENSITIVE	12/10/11	314.93KB	Share
AVR	Coridon Demonstrates 100% Protection using DNA Vaccine	PRICE SENSITIVE	11/10/11	121.21KB	Share
AVR	$5M Equity Funding Package	PRICE SENSITIVE	30/09/11	144.09KB	Share
AVR	Trading Halt	PRICE SENSITIVE	28/09/11	23.35KB	Share
AVR	Preliminary Final Report	PRICE SENSITIVE	01/09/11	441.67KB	Share
AVR	Celxcel Granted Tissue Engineering Patent	PRICE SENSITIVE	29/08/11	238.56KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	29/07/11	508.67KB	Share
AVR	DNA Vaccine Developer Coridon in US Collaboration	PRICE SENSITIVE	20/07/11	243.05KB	Share

AVR Admedus End of Year Update
24/12/13	PRICE SENSITIVE	278.97KB	Share
AVR Admedus Acquires Manufacturing Facility
12/12/13	PRICE SENSITIVE	223.93KB	Share
AVR Allied makes first sale of CardioCel into Europe
08/11/13	PRICE SENSITIVE	184.28KB	Share
AVR Appendix 4C - quarterly
31/10/13	PRICE SENSITIVE	467.99KB	Share
AVR Response to ASX price query
25/10/13	PRICE SENSITIVE	326.34KB	Share
AVR Allied Herpes Phase I Trial progress update
17/10/13	PRICE SENSITIVE	269.31KB	Share
AVR 8 Surgeons get approval to use CardioCel in adult patients
08/10/13	PRICE SENSITIVE	199.58KB	Share
AVR 5 year extension data for Allied's CardioCel
25/09/13	PRICE SENSITIVE	288.61KB	Share
AVR Non-Renounceable Issue Offer Document
23/09/13	PRICE SENSITIVE	501.27KB	Share
AVR Allied announces fully underwritten Rights Issue
23/09/13	PRICE SENSITIVE	312.62KB	Share
AVR Allied Herpes Vaccine Phase I Trial Update
03/09/13	PRICE SENSITIVE	194.72KB	Share
AVR Annual Report to shareholders and Appendix 4E
30/08/13	PRICE SENSITIVE	1.94MB	Share
AVR Allied granted CE Mark for CardioCel
26/08/13	PRICE SENSITIVE	201.44KB	Share
AVR Response to ASX price query
20/08/13	PRICE SENSITIVE	332.66KB	Share
AVR Appendix 4C - quarterly
30/07/13	PRICE SENSITIVE	469.16KB	Share
AVR Allied increases stake in Ian Frazer's Coridon vaccines
01/07/13	PRICE SENSITIVE	196.14KB	Share
AVR Allied's Herpes Vaccine Progresses to Phase 1 Clinical Trial
19/06/13	PRICE SENSITIVE	181.05KB	Share
AVR Allied's CardioCel receives $1.9M grant
03/06/13	PRICE SENSITIVE	225.42KB	Share
AVR Allied's CardioCel in Spotlight at International Conferences
06/05/13	PRICE SENSITIVE	202.44KB	Share
AVR Appendix 4C - quarterly
29/04/13	PRICE SENSITIVE	470.69KB	Share
AVR Allied Announces Additional Early Access for CardioCel
08/04/13	PRICE SENSITIVE	278.62KB	Share
AVR Clinical Trial Extension Study Update - No Calcification
06/03/13	PRICE SENSITIVE	202.33KB	Share
AVR Half Yearly Report
22/02/13	PRICE SENSITIVE	134.2KB	Share
AVR Response to ASX query
19/02/13	PRICE SENSITIVE	352.13KB	Share
AVR Allied announces ISO 13485 certification for CardioCel
13/02/13	PRICE SENSITIVE	202.01KB	Share
AVR Allied's CardioCel superior for seeding stem cells
06/02/13	PRICE SENSITIVE	704.27KB	Share
AVR Appendix 4C - quarterly
30/01/13	PRICE SENSITIVE	449.71KB	Share
AVR Allied's hernia and pelvic floor results
10/01/13	PRICE SENSITIVE	280.04KB	Share
AVR Allied announces successful grant for Coridon's HPV vaccine
20/12/12	PRICE SENSITIVE	266.22KB	Share
AVR Allied Announces Placement and Share Purchase Plan
17/12/12	PRICE SENSITIVE	207.44KB	Share
AVR Trading Halt
13/12/12	PRICE SENSITIVE	75.83KB	Share
AVR Allied's CardioCel shows regeneration in heart valve study
28/11/12	PRICE SENSITIVE	221.5KB	Share
AVR Allied announces successful result for Coridon's HPV vaccine
15/11/12	PRICE SENSITIVE	272.32KB	Share
AVR New contract signals strong year of sales for Allied
07/11/12	PRICE SENSITIVE	252.63KB	Share
AVR Appendix 4C - quarterly
31/10/12	PRICE SENSITIVE	448.04KB	Share
AVR First patients receive Allied's CardioCel
18/10/12	PRICE SENSITIVE	185.72KB	Share
AVR Allied's CardioCel authorised for early use in patients
26/09/12	PRICE SENSITIVE	198.92KB	Share
AVR Preliminary Final Report
31/08/12	PRICE SENSITIVE	580.42KB	Share
AVR Appendix 4C - Fourth Quarter Report
31/07/12	PRICE SENSITIVE	467.39KB	Share
AVR Allied and CSIRO announce stem cell collaboration
03/07/12	PRICE SENSITIVE	257.49KB	Share
AVR Allied submits CE Mark application for CardioCel
05/06/12	PRICE SENSITIVE	74.89KB	Share
AVR Appendix 4C - quarterly
30/04/12	PRICE SENSITIVE	465.2KB	Share
AVR Allied increases stake in Coridon
27/04/12	PRICE SENSITIVE	266.18KB	Share
AVR Allied closes Rights Issue Capital Raising
24/04/12	PRICE SENSITIVE	274.56KB	Share
AVR Allied announces Coridon license to vector technology
17/04/12	PRICE SENSITIVE	278.69KB	Share
AVR Positive Phase II follow up data from CardioCel
05/04/12	PRICE SENSITIVE	182.33KB	Share
AVR Allied announces successful implant of GyneCel
29/03/12	PRICE SENSITIVE	269.02KB	Share
AVR Offer Document for Non-Renounceable Rights Issue
21/03/12	PRICE SENSITIVE	520.16KB	Share
AVR Allied announces ADAPT Patent granted for Singapore
19/03/12	PRICE SENSITIVE	346.75KB	Share
AVR Allied undertake capital raise includes notice under S708AA
16/03/12	PRICE SENSITIVE	275.71KB	Share
AVR Trading Halt
14/03/12	PRICE SENSITIVE	22.23KB	Share
AVR Allied announces successful implant of CardioCel
13/03/12	PRICE SENSITIVE	182.38KB	Share
AVR Allied announces updated regulatory strategy for CardioCel
05/03/12	PRICE SENSITIVE	183.35KB	Share
AVR Half Yearly Report and Accounts
01/03/12	PRICE SENSITIVE	127.73KB	Share
AVR Allied's Coridon to develop HPV Vaccine
28/02/12	PRICE SENSITIVE	153.51KB	Share
AVR Appendix 4C - quarterly
31/01/12	PRICE SENSITIVE	526.44KB	Share
AVR Positive Results in Tissue Heart Valve Study
05/12/11	PRICE SENSITIVE	556.76KB	Share
AVR Allied Healthcare Group Appoints a New CEO of Celxcel
22/11/11	PRICE SENSITIVE	332.05KB	Share
AVR Appendix 4C - quarterly
31/10/11	PRICE SENSITIVE	526.1KB	Share
AVR Allied Healthcare Increases Holding in Coridon
12/10/11	PRICE SENSITIVE	314.93KB	Share
AVR Coridon Demonstrates 100% Protection using DNA Vaccine
11/10/11	PRICE SENSITIVE	121.21KB	Share
AVR $5M Equity Funding Package
30/09/11	PRICE SENSITIVE	144.09KB	Share
AVR Trading Halt
28/09/11	PRICE SENSITIVE	23.35KB	Share
AVR Preliminary Final Report
01/09/11	PRICE SENSITIVE	441.67KB	Share
AVR Celxcel Granted Tissue Engineering Patent
29/08/11	PRICE SENSITIVE	238.56KB	Share
AVR Appendix 4C - quarterly
29/07/11	PRICE SENSITIVE	508.67KB	Share
AVR DNA Vaccine Developer Coridon in US Collaboration
20/07/11	PRICE SENSITIVE	243.05KB	Share

REFRESH

First 2 3

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $5.60		Change 0.330(6.26%)		Mkt cap ! $86.68M

Open	High	Low	Value	Volume
$5.50	$5.60	$5.30	$89.45K	16.14K

Buyers (Bids)

No.	Vol.	Price($)
1	103	$5.30

Sellers (Offers)

Price($)	Vol.	No.
$5.98	992	1

View Market Depth

No.	Vol.	Price($)
1	103	5.300
1	920	5.270
1	613	5.240
1	576	5.200
1	20000	5.150

Price($)	Vol.	No.
5.980	992	1
5.990	3500	1
6.000	3719	2
6.050	20000	1
6.500	230	2

Last trade - 15.29pm 22/08/2025 (20 minute delay)

AVR (ASX) Chart

ANTERIS TECHNOLOGIES GLOBAL CORP. - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available